NewslettersHematopoiesis News Blinatumomab for First-Line Treatment of Children and Young Persons with B-ALL By Laurisa Dohm - November 20, 2023 0 Data were collected for consecutive children and young persons aged 1-24 years with Philadelphia chromosome–positive or Philadelphia chromosome–negative B-ALL who received blinatumomab as first-line therapy. [Journal Of Clinical Oncology] Abstract